Abbott Molecular: Advanced Molecular Diagnostics for Infectious Disease and Oncology Testing

Abbott Molecular is a global leader in in vitro molecular diagnostics, offering PCR-based, FISH-based, and next-generation sequencing (NGS) platforms for infectious disease testing, oncology molecular diagnostics, and pathogen detection. Abbott Molecular’s product portfolio includes the Alinity m system for real-time PCR, the VPAS (Vysis PathVysion Array System) for chromosomal analysis, and the ARCHITECT series for immunoassay diagnostics. In clinical laboratories, Abbott Molecular diagnostics directly inform treatment decisions across HIV, HCV, HBV, CMV, HPV, BCR-ABL monitoring, and HER2 amplification assessment — making it a cornerstone of both infectious disease management and precision oncology.

The Abbott Molecular Product Portfolio

Alinity m — Real-Time PCR Platform

The Alinity m is Abbott’s flagship molecular diagnostics platform, designed for medium-to-high-volume clinical laboratories. Key features:

• Random-access testing: Process up to 6 assays simultaneously from a single sample without batching.
• Automated sample preparation: Integrated magnetic bead-based extraction eliminates manual pipetting.
• Walk-away automation: Minimal operator intervention after loading — ideal for busy hospital laboratories.
• Broad assay menu: HIV-1 viral load, HCV quantification, HBV DNA, CMV, EBV, BK virus, SARS-CoV-2/Flu/RSV combo, and HPV.

The Alinity m SARS-CoV-2 AMP kit received emergency use authorisation (EUA) from the FDA, and the HIV-1 assay is WHO-prequalified — validation benchmarks that matter for public health laboratories and donor screening programmes in India.

Vysis FISH Probes

Abbott Molecular’s Vysis probe portfolio is one of the most extensive in clinical cytogenetics and oncology FISH. Key probe categories:

• Vysis LSI (Locus-Specific Identifier) Probes: Used for gene amplification (HER2, EGFR) and deletion (TP53, 1p/19q) detection.
• Vysis CEP (Chromosome Enumeration Probes): Centromeric probes for aneuploidy detection in prenatal samples.
• Vysis PathVysion HER2 DNA Probe Kit: FDA-approved companion diagnostic for HER2-targeted therapy eligibility in breast cancer.
• Vysis BCR-ABL ES Dual Colour Translocation Probe: Gold-standard FISH probe for CML diagnosis and residual disease monitoring.

RealTime PCR Assays — m2000 Platform

The Abbott m2000 RealTime system is a semi-automated PCR platform widely deployed in virology and microbiology laboratories. It supports quantitative and qualitative detection across the same assay menu as the Alinity m, with a lower throughput footprint suitable for hospital laboratories running 20–50 samples per batch.

Abbott Molecular vs Competing Platforms: Technical Comparison

Molecular Diagnostics Workflow: Infectious Disease Testing

For a virology laboratory implementing HIV-1 viral load testing using Abbott Molecular:

Sample Collection (EDTA plasma) → Sample Registration in LIS → Alinity m Loading → Automated Extraction (magnetic bead) → RT-PCR Amplification → Real-Time Fluorescence Detection → Automated Quantification → Result Review → Report Generation

DSS Imagetech provides institutional procurement of Abbott Molecular diagnostics including instrument installation, IQ/OQ validation, staff training, and ongoing reagent supply chain management across India.

Oncology Molecular Diagnostics: FISH and BCR-ABL Monitoring

In oncology, Abbott Molecular’s contribution centres on three key applications:

• HER2 FISH Testing: The Vysis PathVysion kit provides FDA-cleared HER2 gene amplification status for breast cancer patients being considered for trastuzumab therapy. It calculates the HER2:CEP17 ratio and average HER2 copy number per cell, following ASCO/CAP 2018 guidelines.
• BCR-ABL Quantification: The RealTime BCR-ABL IS assay, standardised to the International Scale (IS), provides Major Molecular Response (MMR, ≥3-log reduction) and Deep Molecular Response (DMR) monitoring for CML patients on TKI therapy.
• 1p/19q Codeletion by FISH: Vysis probes detect this marker of oligodendroglioma, which carries both diagnostic and prognostic significance, and predicts response to PCV chemotherapy.

Infectious Disease Testing: Comprehensive Pathogen Detection

Abbott Molecular’s infectious disease testing portfolio supports pathogen detection across a wide spectrum:

• HIV-1/2: Viral load quantification, drug resistance genotyping, and qualitative infant diagnosis.
• HCV: Quantitative viral load for antiviral treatment initiation and response monitoring.
• HBV: DNA quantification for treatment decisions in chronic hepatitis B.
• CMV: Quantification in transplant recipients to guide pre-emptive antiviral therapy.
• HPV: Genotyping for high-risk strains (16/18) in cervical cancer screening programmes.
• Respiratory Viruses: SARS-CoV-2, Influenza A/B, RSV detection from NPS samples.

Implementation and Accreditation Considerations in India

Molecular laboratories in India implementing Abbott Molecular platforms must address several regulatory and operational requirements. NABL ISO 15189 accreditation requires documented validation studies for each assay, including analytical sensitivity, specificity, linearity, and precision studies. Abbott provides complete assay validation packages, and DSS Imagetech’s application team assists in adapting these to the local regulatory framework.

Request a Technical Consultation

Are you evaluating solutions for your laboratory or diagnostic centre? DSS Imagetech’s technical specialists provide instrument demonstrations, application-specific guidance, and end-to-end installation support across India. Connect with an expert today to discuss how our portfolio can elevate your workflow.

📧 Contact DSS Imagetech — Request a Consultation